hotspot -WSS

hotspot

author：comprehensive 2025-09-30 00:48:28 - browse：43816

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Scientists at the Food and Drug Administration have two big questions about Eli Lilly’s experimental Alzheimer’s drug donanemab ahead of a panel of outside experts that it is convening on Monday:

Should the patients who receive the medicine be limited based on PET scans of a protein called tau that Eli Lilly used as a key criteria for trying to determine whether they should receive the drug? That could reduce usage of the medicine by adding a barrier to its use.

And how do the potential risks of using the drug compare to its benefits? The FDA points to one analysis, admittedly with missing data, that could indicate patients who receive the drug have a higher risk of dying.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： STAT Virtual Event: Putting AI to the Test

explore

WSS

How to make over

As obesity drug market grows, telehealth companies court payers

Vivek Ramaswamy made waves in the debate, much as in biotech

CDC advisers recommend seasonal use of Pfizer RSV shot

Biotech stock slump in 2023: awaiting the turnaround

Republicans love RFK Jr. What's that tell us about health in 2024?

focus

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

BioMarin wins approval for gene therapy to treat hemophilia A

Changes to biosimilar regulatory framework must prioritize patients

After affirmative action ruling, medical educators look to 'holistic review'

PBMs are inflating the cost of generic drugs. They must be reined in

Hepatitis C has a cure — but many Americans still lack access to it

How AI helped researchers track recovery from depression

Cancer drug shortages should be causing more outrage

Biotech lab space demand falls sharply

Trump demands the U.S. pay no more for drugs than other countries … again

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

leisure time

PBMs are inflating the cost of generic drugs. They must be reined in

CDC's new outbreak response network to include Northeastern

STAT Virtual Event: Putting AI to the Test

It's been 20 years since Dolly the sheep. Where's my clone?

National associations that represent hospice owe an apology

Biotech stock slump in 2023: awaiting the turnaround

leisure time

explore

leisure time

explore